MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second Quarter of 2022


Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, announced today that the Company and its digital therapeutics technology, iSTRYM, have been certified as Health Insurance Portability and Accountability Act (HIPAA) compliant.

iSTRYM becoming HIPAA compliant reflects MINDCURE’s commitment to achieving the highest standards of medical data protection and privacy. HIPAA compliance certification is the next step for the Company in working towards having the iSTRYM technology platform classified a ‘Software as a Medical Device’ by the FDA.

Kelsey Ramsden, President & CEO of MINDCURE, stated, “Receiving HIPAA compliance is a significant milestone for MINDCURE, which supports our goal of commercially deploying iSTRYM in the second quarter of 2022, as well as generating near-term revenue from the platform. We developed iSTRYM as a drug-agnostic tool that we will be able to scale beyond psychedelics and into other therapeutic fields, which could result in additional revenue opportunities for MINDCURE in the future.”

iSTRYM is a mental health practice management software platform that empowers healthcare providers to deliver innovative and personalized healing solutions to patients. MINDCURE is positioning iSTRYM to become the industry’s distribution network for science-based, evidence-backed protocols and Artificial Intelligence data systems.

Geoff Belair, MINDCURE’s Chief Technology Officer, said, “We want to be the company that people trust with their minds, and achieving HIPAA is the first step of many in building that trust.  At MINDCURE we passionately defend data privacy and will always ensure it is a core part of what we provide.”

The Company announced in October that it had exceeded its previously announced target of 10 partner clinics for iSTRYM by the end of 2021, which currently includes partnerships with 20 ketamine clinics in nine states across the United States and three provinces in Canada.

“Our ability to partner with these clinics serves to validate our confidence in the iSTRYM platform and its value to patients and clinicians,” continued Ms. Ramsden. “iSTRYM was created with the aim of shifting the paradigm of care and access to psychedelic-assisted psychotherapy, reducing the cost of care, improving patient outcomes, and providing a distribution network for psychedelic companies to distribute protocols.”

In August, the Company released the minimum viable product (“MVP”) of iSTRYM’s digital therapeutics (DTx) technology to partner clinics across North America. MINDCURE also plans to expand iSTRYM software deployment to address the mental health markets in the United Kingdom and Europe by the fourth quarter of 2022.


MINDCURE Signs Exclusive Digital Clinical Data Licensing Agreement with ATMA Journey Centers


Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research in psychedelics, announced today an exclusive data licensing agreement with ATMA Journey Centers Inc. (“ATMA”), a pioneer in the psychedelic therapy industry and the first commercial company in Canada to legally treat a palliative patient with psychedelic-assisted therapy using psilocybin. This agreement is an extension to an existing partnership, whereby ATMA will grant MINDCURE an exclusive license to ATMA data from patients using the iSTRYM digital therapeutics software, with the intended goal of further optimizing the platform.

MINDCURE is positioning iSTRYM to be the industry’s distribution network for science-based, evidence-backed protocols and AI (Artificial Intelligence) data systems. iSTRYM is a first-of-its-kind software application that optimizes the healing journey for patients and clinicians — before, during, and after therapy sessions. iSTRYM was built to shift the paradigm of care and access for psychedelic-assisted psychotherapy, reducing the cost of care, improving patient outcomes, and providing a distribution network for psychedelic companies to distribute protocols. As a drug agnostic platform, iSTRYM was built to support not only any type of psychedelic molecule within a treatment protocol, but to support protocols which utilize existing drugs on the market or therapeutic protocols that might not need a drug at all, as in traditional talk therapy.

MINDCURE plans initially to service psychedelic clinics and to expand into integrated clinics, both traditional and psychedelic, and eventually to the broader mental health market. In August, the Company released the minimum viable product (MVP) version of iSTRYM into partner clinics across North America. MINDCURE plans to begin full commercial deployment in Q1 of 2022.

“We are thrilled to expand our collaboration with the team at ATMA. With data being a core component to refining iSTRYM, having access to ATMA’s network of therapists and anonymized patient data will improve our ability to provide the tools, protocols, and treatments to therapists, and enable us to address a global mental health crisis in need of a solution,” said Kelsey Ramsden, MINDCURE President and CEO. “ATMA’s growing clinical footprint in Canada along with its recently inaugurated center in Costa Rica gives MINDCURE the opportunity to deploy iSTRYM, with the intended goal of optimizing treatments for its patients and to expose iSTRYM to the data necessary to build the platform into one trusted by therapists and patients around the world.”

“Our partnership with ATMA is an exciting opportunity for MINDCURE to demonstrate the effectiveness of iSTRYM’s treatment protocols and to identify those treatment components that are associated with optimal client outcomes. This is at the core of what we have built iSTRYM to do,” said Ty Tashiro, MINDCURE Senior Translational & Psychometric Architect. “This particular collaboration will allow us to deploy iSTRYM’s multifaceted assessment capabilities, including biometrics, natural language processing and unique psychometrics, to create a responsive, personalized treatment experience.”

“We look forward to helping MINDCURE develop iSTRYM into the leading digital therapeutics platform for therapists conducting psychedelic-assisted psychotherapy,” said David Harder, Co-CEO and Co-Founder of ATMA. “Real data from patients will further strengthen and improve the protocols we use and the effectiveness of treatments we deliver at our Journey Centers.”

In related news, MINDCURE successfully launched the minimum viable product (MVP) of iSTRYM on August 26, 2021. The Company is on track to expand into over ten clinics across Canada and the U.S. within the MVP beta testing program in Q4 2021.


MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company’s Psychedelic Digital Therapeutics Technology Platform


Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has entered into a partnership with Speak Ai Inc. (“Speak Ai). The Canadian-based technology company helps individuals and organizations analyze media, language, and metadata to automatically generate valuable insights through machine learning. MINDCURE will be integrating the platform’s capabilities into iSTRYM, and will also work with Speak Ai to develop proprietary, technology-based mental health solutions.

By combining audio, video, and text analysis with metadata in a single platform, Speak Ai has developed a comprehensive solution for generating personalized insights to improve research and personal wellbeing. Their technology has been honed over several years of development, research, and experience, and the organization has built a strong reputation within the psychedelic community.

“We are proud to partner with MINDCURE today to help build iSTRYM into a powerful solution for therapists and patients around the world,” said Tyler Bryden, Speak Ai Founder. “I have had the privilege to witness the potential of psychedelic-assisted therapies in my own life and in the lives of amazing people around me who are healing from anxiety, depression, PTSD, traumatic brain injuries, and more.”

This partnership will result in driving data for iSTRYM, taking unstructured data, and creating structure and metrics for the platform integration. Natural language processing with machine learning allows MINDCURE to drive insights for the therapist and patient. This information is often difficult to capture using traditional methods during the course of therapy.

“By developing solutions with empathy, we can improve the level of care to help people avoid, navigate through and recover from crises. We share the belief with MINDCURE that technology can play a major role in enabling these potentially life-changing and individual therapies to succeed at scale,” continued Bryden.

“We are excited to work with Tyler and the team at Speak Ai because of their intimate knowledge of the value of technology in the therapeutic and integration process within psychedelics and the traditional therapeutic model,” said MINDCURE CEO and President Kelsey Ramsden“We will be building custom integrations with Speak Ai for the iSTRYM platform that allow us to marry sentiment with biometric data, location, weather, and a variety of other variables to help optimize our integration protocols and provide individuals with quantified care at scale globally, all with the stated goal of advancing Mental Wealth, rooted in data.”